The emerging role of cytokines in the treatment of advanced melanoma

Ulrich Keilholz, Alexander M.M. Eggermont

Onderzoeksoutput: Bijdrage aan tijdschriftArtikel recenserenpeer review

27 Citaten (Scopus)


Cytokine-based treatment regimens have been evaluated for advanced melanoma in a number of phase I and phase II trials within the last decade. Treatment with interleukin-2 (IL-2) as a single agent has resulted in response rates of approximately 15%, if a high dose of IL-2 is administered. Combination of interferon-α (IFNα) and high dose IL-2 yields response rates ranging from 10 to 41%. Response rates exceeding 50% have been reported with chemoimmunotherapy, if the treatment regimens included at least the three agents IL-2, IFNα and cisplatin. Recent randomized trials have evaluated the impact of these drugs on the survival of patients with advanced melanoma. The current 'state of the art' is discussed in this review. Copyright (C) 2000 S. Karger, AG, Basel.

Originele taal-2Engels
Pagina's (van-tot)89-95
Aantal pagina's7
TijdschriftOncology (Switzerland)
Nummer van het tijdschrift2
StatusGepubliceerd - feb. 2000
Extern gepubliceerdJa


Duik in de onderzoeksthema's van 'The emerging role of cytokines in the treatment of advanced melanoma'. Samen vormen ze een unieke vingerafdruk.

Citeer dit